| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epithelial Carcinogenesis Laboratory, Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 OTL, England
A series of 152 human bladder tumors, 14 bladder tumor cell lines, and 1 immortal urothelial cell line were examined by single-strand conformation polymorphism (SSCP) and designed restriction fragment length polymorphism analyses for mutations in exons 1 and 2 of the H-ras gene. Nine tumors (6%) contained mutations. There was complete concordance between SSCP and restriction fragment length polymorphism analyses. Six mutations in exon 1 and three in exon 2 were identified by SSCP analysis. Subsequent restriction fragment length polymorphism analysis showed that of the exon 1 mutations, four were in codon 12 and two in codon 13, and all three exon 2 mutations were in codon 61. Eight mutations were confirmed by direct sequencing. One codon 13 mutation could not be identified by direct sequencing. Distinct strand mobility shifts detected by SSCP analysis identified specific point mutations, and in all cases, strands containing different mutations migrated differently. The base substitutions identified in these bladder tumors were diverse and included four transversions (three G
T and one AT) and four transitions (two GA and two AG). This pattern of base substitutions is compatible with interactions of the urothelium with more than one class of environmental agent during bladder tumor development. No correlation was found between tumor grade and/or stage and the presence of H-ras mutation. We conclude that H-ras mutation does not play a role in the development of the majority of transitional cell tumors of the bladder.
1 To whom requests for reprints should be addressed.
Received 6/10/92. Accepted 10/19/92.
This article has been cited by other articles:
|
|
 |
|
  J. E. Rosenberg and W. C. Hahn Bladder cancer: modeling and translation Genes & Dev., March 15, 2009; 23(6): 655 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Veerakumarasivam, H. E. Scott, S.-F. Chin, A. Warren, M. J. Wallard, D. Grimmer, K. Ichimura, C. Caldas, V. P. Collins, D. E. Neal, et al. High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53 Clin. Cancer Res., May 1, 2008; 14(9): 2527 - 2534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Johne, I. Roots, and J. Brockmoller A Single Nucleotide Polymorphism in the Human H-ras Proto-oncogene Determines the Risk of Urinary Bladder Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 68 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Stoeber, R. Swinn, A. T. Prevost, P. de Clive-Lowe, I. Halsall, S. M. Dilworth, J. Marr, W. H. Turner, N. Bullock, A. Doble, et al. Diagnosis of Genito-Urinary Tract Cancer by Detection of Minichromosome Maintenance 5 Protein in Urine Sediments J Natl Cancer Inst, July 17, 2002; 94(14): 1071 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Knowles What we could do now: molecular pathology of bladder cancer Mol. Pathol., August 1, 2001; 54(4): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ota, M. Asamoto, H. Toriyama-Baba, F. Yamamoto, Y. Matsuoka, T. Ochiya, T. Sekiya, M. Terada, H. Akaza, and H. Tsuda Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis Carcinogenesis, July 1, 2000; 21(7): 1391 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Burchardt, T. Burchardt, A. Shabsigh, A. De La Taille, M. C. Benson, and I. Sawczuk Current Concepts in Biomarker Technology for Bladder Cancers Clin. Chem., May 1, 2000; 46(5): 595 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zujewski, I. D. Horak, C. J. Bol, R. Woestenborghs, C. Bowden, D. W. End, V. K. Piotrovsky, J. Chiao, R. T. Belly, A. Todd, et al. Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer J. Clin. Oncol., February 14, 2000; 18(4): 927 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Asamoto, T. Ochiya, H. Toriyama-Baba, T. Ota, T. Sekiya, M. Terada, and H. Tsuda Transgenic rats carrying human c-Ha-ras proto-oncogenes are highly susceptible to N-methyl-N-nitrosourea mammary carcinogenesis Carcinogenesis, February 1, 2000; 21(2): 243 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Mostafa, S. A. Sheweita, and P. J. O'Connor Relationship between Schistosomiasis and Bladder Cancer Clin. Microbiol. Rev., January 1, 1999; 12(1): 97 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Conejo, T. Parra, M. Cantero, A. Jimenez, V. Granizo, V. Gabriel de Arriba, and F. Carballo Detection of H-ras Mutations in Urine Sediments by a Mutant-enriched PCR Technique Clin. Chem., July 1, 1998; 44(7): 1570 - 1572. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
